Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD40 ligand - Celldex Therapeutics

Drug Profile

CD40 ligand - Celldex Therapeutics

Alternative Names: Avrend; CD40-L; rHuCD40 ligand; rHuCD40L

Latest Information Update: 04 May 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Celldex Therapeutics Inc
  • Class Recombinant proteins
  • Mechanism of Action B cell stimulants; CD40 ligand stimulants; Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Immunological disorders
  • Discontinued Head and neck cancer; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours; Viral infections

Most Recent Events

  • 20 Apr 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 18 Mar 2016 Early research in Cancer in USA (Parenteral)
  • 10 Apr 2009 CD40 ligand licensed to Celldex Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top